OClawVPS.com
SciBase
Edit

SciBase

https://www.scibase.com/
Last activity: 07.04.2026
Active
Categories: AIDermatologyDiagnosticsHealthcareMedicalTech
Leading developer of augmented intelligence-based solutions for skin disorders
Likes
462
Followers
291
Mentions
187
Location: Sweden
Employees: 11-50
Phone: +46 8 410 620 00
Total raised: $8.58M
Founded date: 1998

Investors 2

Funding Rounds 1

DateSeriesAmountInvestors
31.05.2021-$8.58M-

Mentions in press and media 187

DateTitleDescription
07.04.2026SciBase reaches milestone with over 400,000 tests sold with NevisenseSciBase reaches milestone with over 400,000 tests sold with Nevisense Tue, Apr 07, 2026 08:00 CET Report this content STOCKHOLM, Sweden – April 7, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic...
13.03.2026Interim reportInterim report Fri, Mar 13, 2026 08:00 CET Report this content January 1 – December 31, 2025 The fourth quarter in figures Net sales were TSEK 12,475 (8,598), +45%, cleared for currency effects +57%. The loss after tax was TSEK 25,300 (21,6...
10.03.2026New Study Positions Nevisense’s EIS as a valuable and sensitive tool for assessing skin barrier impairmentNew Study Positions Nevisense’s EIS as a valuable and sensitive tool for assessing skin barrier impairment Tue, Mar 10, 2026 13:00 CET Report this content STOCKHOLM, Sweden – March 10, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a le...
05.03.2026New Publication: US clinicians’ real-world Nevisense experience improves melanoma detectionNew Publication: US clinicians’ real-world Nevisense experience improves melanoma detection Thu, Mar 05, 2026 08:00 CET Report this content STOCKHOLM, Sweden – March 5, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer ...
02.03.2026SciBase receives approval by FDA for extended labelling in the USSciBase receives approval by FDA for extended labelling in the US Mon, Mar 02, 2026 08:00 CET Report this content STOCKHOLM, Sweden – March 2, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic sol...
19.02.2026SciBase’s Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanomaSciBase’s Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma Thu, Feb 19, 2026 13:30 CET Report this content STOCKHOLM, Sweden – February 19, 2026 – SciBase Holding AB ...
17.02.2026A new study demonstrates that Nevisense can predict atopic dermatitis in NewbornsA new study demonstrates that Nevisense can predict atopic dermatitis in Newborns Tue, Feb 17, 2026 15:00 CET Report this content STOCKHOLM, Sweden – February 17, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-...
06.02.2026Recalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issueRecalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issue Fri, Feb 06, 2026 08:00 CET Report this content In accordance with the terms and conditions for warrants of series ...
26.01.2026Change of date for publication of the year-end report for the financial year 2025Change of date for publication of the year-end report for the financial year 2025 Mon, Jan 26, 2026 17:45 CET Report this content The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has resol...
22.01.2026Increased commitment in SciBase rights issueIncreased commitment in SciBase rights issue Thu, Jan 22, 2026 15:15 CET Report this content STOCKHOLM, Sweden – January 22, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin di...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In